相关实验视频
Updated: Jan 12, 2026

07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
49.2K
治疗疼痛的临床开发中的通道抑制剂:集中审查
Crystal Banh1,2, Aleksandar Sic1,3, Nebojsa Nick Knezevic4,5,6
1Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, IL, 60657, USA.
CNS drugs
|November 3, 2025
概括
针对特定通道 (Nav1.7和Nav1.8) 的新型非阿片类止痛药显示出有前途. 苏泽特里金 (VX-548) 是第一个FDA批准的Nav1.8抑制剂,为更安全,非成性疼痛管理提供了希望.
科学领域:
- 疼痛研究 疼痛研究
- 神经药理学神经药理学
- 药物发现 药物发现
背景情况:
- 慢性和神经病痛很难用目前的药物治疗,如阿片类药物和NSAIDs.
- 电压通道Nav1.7和Nav1.8是缓解疼痛的关键目标,因为它们在疼痛信号传递中的作用.
- 有限的疗效和安全问题阻碍了传统的疼痛疗法.
研究的目的:
- 审查用于疼痛管理的新型通道抑制剂.
- 要突出suzetrigine (VX-548) 和其他研究药物.
- 讨论在开发非成止痛药方面的挑战和未来战略.
主要方法:
- 对通道抑制剂的临床发展的审查.
- 专注于Nav1.8抑制剂,如苏泽特里金 (VX-548).
- 对包括拉菲纳米德,OLP-1002,LTGO-33和HBW-004285.5在内的研究药物的分析.
主要成果:
- 苏泽特里金 (VX-548) 是FDA批准的第一种用于治疗急性疼痛的Nav1.8抑制剂.
- 尽管存在早期的挑战,但正在进行的试验显示出新一类止痛药的前景.
- 新兴战略正在解决选择性和目标副作用等问题.
结论:
- 新型通道抑制剂为阿片类药物和NSAIDs提供了潜在的替代品.
- 结构生物学和精密医学的进步对于开发有效的疼痛治疗非常重要.
- 未来的疼痛疗法旨在更安全,更有效,并且不成.
相关概念视频
Analgesia and Pain Management
1.5K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.5K
Voltage-gated Ion Channels
10.3K
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
10.3K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.7K
Non-gated Ion Channels
8.0K
Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
8.0K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K
Nociception
33.0K
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
33.0K

